tbuckley/cabot-search huggingface dataset:
FRI0022 Glutamine metabolism plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis
Authors: S Takahashi, J Saegusa, H Yamada, Y Ichise, I Naka, T Okano, K Akashi, S Sendo, Y Ueda, A Onishi, A Morinobu
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Many signaling pathways activated under inflammatory and hypoxic conditions have profound effects on intracellular metabolism to support cell growth and survival. The recent findings of cancer-specific metabolic changes, including increased glucose and glutamine consumption, has provided new therapeutic targets for consideration. The microenvironment in inflamed joints in RA is also characterized by hypoxia and low concentration of nutrients, and fibroblast-like synoviocytes from RA patients (RA-FLS) is known to have several tumor-like characteristics. However, the role of glucose and glutamine metabolism in the aberrant proliferation of these cells is unclear. <h3>Objectives</h3> We evaluated the role of these metabolic pathways in RA-FLS proliferation and in autoimmune arthritis in SKG mice. <h3>Methods</h3> The expression of glycolysis- or glutaminolysis-related enzymes was evaluated by real-time PCR and Western blotting, and the intracellular metabolites were evaluated by metabolomic analyses. The effects of glucose or glutamine on RA-FLS cell growth were investigated using glucose- or glutamine-free medium. Glutaminase 1 (GLS1) siRNA and the GLS1 inhibitor compound 968 were used to inhibit GLS1 in RA-FLS. Arthritis was induced in SKG mice by zymosan A injection. Compound 968 was used to study the effect of GLS1 inhibition on Zymosan A-injected SKG mice. Ki-67-positive cells were analyzed by immunohistochemistry. <h3>Results</h3> GLS1 expression was increased in RA-FLS, and metabolomic analyses revealed that glutamine and glutamate consumption were increased in RA-FLS. RA-FLS proliferation was reduced under glutamine-deprived, but not glucose-deprived conditions. Cell growth of RA-FLS was inhibited by GLS1 siRNA transfection or GLS1 inhibitor treatment. Silencing of GLS1 in RA-FLS did not affect IL-6 or MMP-3 production in supernatants. GLS1 expression in RA-FLS was not affected by pro-inflammatory cytokine stimulation. Compound 968 ameliorated the autoimmune arthritis and decreased the number of Ki-67-positive synovial cells in SKG mice. <h3>Conclusions</h3> Our findings suggested that glutamine metabolism plays an important role in regulating RA-FLS proliferation, without being affected by pro-inflammatory cytokine stimulation or affecting cytokine production, and may be a novel therapeutic target for RA. <h3>Disclosure of Interest</h3> None declared
AB0560 Study on streptococcal infection relationship with henoch-schonlein purpura in children
Authors: F Li, H Zeng
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> To study hemolytic Streptococcus infection relationship with Henoch-Schonlein Purpura in children. <h3>Methods</h3> 42 cases in children with Henoch-Schonlein Purpura (Observer Group) and healthy children in 40 cases of physical examination (the control group) for blood antistreptolysin O (ASO) detection, observation group at the same time children are divided into (belly-non-abdominal Purpura and Purpura group set and repeatedly attacks groups and the Group of non-recurrent) for statistical analysis. <h3>Results</h3> Observation group in the blood ASO detection positive 22 cases, accounted for 52.4%; normal control group children 40 cases, blood ASO detection positive 2 cases, accounted for 5%, both comparison differences has significantly significance (χ<sup>2</sup>=22.22, p&lt;0.01); abdominal type Purpura children with 23 cases, blood ASO detection positive 17 cases, accounted for 73.9%; non-abdominal type Purpura children with 19 cases, blood ASO detection positive 5 cases, accounted for 26.3%, both comparison differences has significantly significance (χ<sup>2</sup>=9.45, p&lt;0.01); 14 cases in children with recurrent Henoch-Schonlein Purpura, ASO blood test positive in 12 cases, 85.7%, non-recurrent attacks of 28 cases of children with Henoch-Schonlein Purpura, ASO blood test positive in 10 cases, 35.7%, comparing the two differences are significant (χ<sup>2</sup>=9.35, p&lt;0.01). <h3>Conclusions</h3> Streptococcal infections may be the important factor relatated to Henoch-Schonlein Purpura in children.Purpura and Purpura of abdominal type recurrence is related with streptococcal infection, which is the great value to treatment. <h3>Disclosure of Interest</h3> None declared
SP0154 Rationale to target immune memory residing in inflamed tissues
Authors: H-D Chang
Journal: Annals of the Rheumatic Diseases (2017)

T helper (Th) lymphocytes play a major role in the regulation of immune responses and are thought to initiate and drive chronic rheumatic inflammation. Memory Th lymphocytes persist in the inflamed tissue and are refractory to therapeutic intervention. In chronic inflammation Th lymphocytes have undergone molecular adaptations, such as the upregulation of Twist1 and the microRNA miR-148a, which are not found in circulating Th lymphocytes, and support the survival of the Th cells within the inflamed tissue. Within the inflamed tissue, the Th lymphocytes constantly recruit and activate inflammatory cells, such as monocytes/macrophages and granulocytes through the secretion of particular chemokines and interleukins. The monocytes/macrophages in turn can recruit more Th cells into the inflamed tissue. Disrupting this vicious circle by specifically targeting the memory Th cells resident in the inflamed tissue by interfering with their molecular adaptations could be an interesting therapeutic option. <h3>Disclosure of Interest</h3> None declared
Complementary and Alternative Medical Education
Authors: Samuel Neff
Journal: Annals of Internal Medicine (2004)

Letters6 January 2004Complementary and Alternative Medical EducationSamuel Neff, MDSamuel Neff, MDFrom Graduate Hospital, Philadelphia, PA 19146.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-1-200401060-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I disagreed with the first sentence of the abstract of “Complementary and Alternative Medical Therapies: Implications for Medical Education” (1) and with most of the rest of the article as well. Although we try to limit ourselves to evidence-based approaches for medical treatment, the authors would have medical education become a scientific “free-fire zone” for every unvalidated whim, notion, and economic and political agenda in our diverse society. Instead of making an eloquent argument that we should drop our standards for the medical curriculum to below those for medical practice (and publication), the authors would have made ...References1. Wetzel MS, Kaptchuk TJ, Haramati A, Eisenberg D. Complementary and alternative medical therapies: implications for medical education. Ann Intern Med. 2003;138:191-6. [PMID: 12558358] LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Samuel Neff, MDAffiliations: From Graduate Hospital, Philadelphia, PA 19146. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComplementary and Alternative Medical Therapies: Implications for Medical Education Miriam S. Wetzel , Ted J. Kaptchuk , Aviad Haramati , and David M. Eisenberg Complementary and Alternative Medical Education Peter Manu Complementary and Alternative Medical Education Edzard Ernst Complementary and Alternative Medical Education Mary P. Guerrera Complementary and Alternative Medical Education Miriam S. Wetzel , Ted J. Kaptchuk , David M. Eisenberg , and Aviad Haramati Metrics Cited byPatient and Medical Education on Complementary and Alternative Medicine 6 January 2004Volume 140, Issue 1Page: 67KeywordsMedical educationSafety ePublished: 6 January 2004 Issue Published: 6 January 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
SAT0604 Autologous blood and corticosteroid local injection in treatment of plantar fasciitis (randomized, controlled multicenter clinical trial)
Authors: A Karimzadeh, SA Raeissadat, S Erfani fam, L Sedighipour
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Plantar fasciitis is the most common cause of heel pain. Local injection modalities are among treatment options in patients with resistant pain. <h3>Objectives</h3> The aim of the present study was to evaluate the effect of local autologous blood compared with corticosteroid local injection in treatment of plantar fasciitis. <h3>Methods</h3> In this randomized controlled multicenter study, 36 patients with chronic plantar fasciitis were recruited. Patients were allocated randomly into 3 treatment groups: local autologous blood, local corticosteroid injection and control groups receiving no injection. Patients were assessed with Visual Analogue Scale (VAS), Pressure Pain Threshold (PPT) and Plantar Fasciitis Pain/Disability Scale (PFPS) before treatment, 4 and 12 weeks post therapy. <h3>Results</h3> Variables of pain and function improved significantly in both corticosteroid and autologous blood groups compared to control group. At 4 weeks following treatment, patients in corticosteroid group had significantly lower levels of pain than patients in autologous blood and control groups (higher PPT level, lower PFPS and VAS). After 12 weeks of treatment both corticosteroid and autologous blood groups had lower average levels of pain than control group. The corticosteroid group showed an early sharp and then more gradual improvement in pain scores but autologous blood group had steady gradual drop in pain. <h3>Conclusions</h3> Autologous blood and corticosteroid local injection both can be considered as effective methods in the treatment of chronic plantar fasciitis. These treatments decrease pain and improve function significantly compared to control group. <h3>Disclosure of Interest</h3> None declared
AB0790 Hyperuricemia in psoriatic arthritis: prevalence and associated factors
Authors: T Gudu, A Peltea, A Balanescu, V Bojinca, D Opris, D Predeteanu, R Ionescu
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Hyperuricemia is frequent in psoriatic arthritis (PsA) and it seems to be related to metabolic syndrome rather than to extensive psoriatic skin disease [1]. <h3>Objectives</h3> The objective of this study was to evaluate the prevalence of hyperuricemia in PsA patients and to identify the associated factors. <h3>Methods</h3> Design: cross-sectional study, including consecutive, unselected, adult PsA patients. Data collection: demographic variables (age, gender, disease duration), clinical variables (affected joints, current moderate/severe psoriasis, nail disease, axial involvement, enthesitis, dactylitis), biological factors (acute phase reactants), treatment-related variables (non-steroidal antiinflamatory drugs, corticosteroids, synthetic and biologic disease modifying drugs) and comorbidities [2]. Hyperuricemia was defined as uric acid level above 6.8 mg/dl [3]. Statistical analysis: the factors that were potentially associated with hyperuricemia were assessed by Spearman correlation and uni- and multivariate logistic regressions. <h3>Results</h3> In all, 120 PsA patients were included in the study: 69 (57.5%) women, mean age±standard deviation 54±11.8 years, mean disease duration 7±7.4 years; 24 (20%) had moderate/severe psoriasis and 30 (25%) were taking a biologic. A high percentage of patients had cardiovascular comorbidities, i.e., dyslipidemia 80%, hypertension 51.7%, obesity 34.2% and cardiovascular events 34.2%. Around a quarter of patients had hyperuricemia (33; 27.5%). Hyperuricemia was significantly associated with obesity, diabetes, ischemic heart disease and hypertension, but there was no correlation with current skin psoriasis. In the multivariate analysis, it was best explained by diabetes (odds ratio: 4.95, [95% confidence intervals: 1.47; 16.67]), ischemic heart disease (3.61 [1.00; 12.98]) and obesity (1.86 [1.04; 3.32]). <h3>Conclusions</h3> Hyperuricemia in PsA is associated with metabolic syndrome rather than skin psoriasis, but further longitudinal studies are needed to identify causal relationships. <h3>References</h3> Bruce IN, Schentag CT, Gladman DD. Hyperuricemia in psoriatic arthritis: prevalence and associated features. J Clin Rheumatol 2000;6(1):6–9. Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis 2016;75(6):965–73. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987;82(3):421–6. <h3>Disclosure of Interest</h3> None declared
AB0251 In rheumatoid arthritis erosions are more frequent in the feet than in the hands
Authors: ML Andersson, B Svensson, K Forslind
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Joint destruction in patients with rheumatoid arthritis (RA) is mostly evaluated by scoring radiographs of both hands and feet using the Sharp van der Heijde or Larsen scoring methods. In contrast, DAS28, the most commonly used composite measure of inflammation measure, does not include the feet. <h3>Objectives</h3> To study the distribution of erosions in hand and wrist (hands) and feet in early RA and elucidate if the feet should be included also in composite measures of inflammation <h3>Methods</h3> This study comprises 1 052 patients from the BARFOT study of patients with early RA, recruited 1992–2006. Radiographs of hands and feet were performed at baseline, 1, 2, 5 and 8 years and evaluated by the Sharp van der Heijde scoring (SHS) method (32 joints in the hands and 12 in the feet). Disease activity at baseline was measured by the DAS28. <h3>Results</h3> In the feet there were significantly more eroded joints in percent of examined joints at all time points (p&lt;0.001), and higher erosion scores in percent of maximum erosion score at 5 and 8 years (0.037 and 0.021 respectively), compared with the hands. There were no differences in mean joint space narrowing (JSN) between hands and feet at any time point. Patients with erosions only in the feet had significantly lower DAS28, mean 4.59, compared with the patients in the other groups, mean 5.03 in the no erosions group p=0.031, mean 5.17 in the group with erosions only in the hands, p=0.013, and mean 5.15 in the group with erosions in both hands and feet, p=0.031. <h3>Conclusions</h3> Joint destruction over time was more pronounced in the feet than in the hands. Baseline erosions limited to the feet were associated with low disease activity, suggesting that inflammation localized to the feet may not be reflected by DAS28. These observations may have relevance to the evaluating of disease activity and progression in the individual patient. Possibly inclusion of the feet to DAS28 might improve the validity of this disease activity measure. <h3>Disclosure of Interest</h3> None declared
Right Atrial Pacing Impairs Cardiac Function During Resynchronization Therapy
Authors: Alain Bernheim, Peter Ammann, Christian Sticherling, Peter Burger, Beat Schaer, Hans Peter Brunner-La Rocca, Jens Eckstein, Stephanie Kiencke, Christoph Kaiser, Andre Linka, Peter Buser, Matthias Pfisterer, Stefan Osswald
Journal: Journal of the American College of Cardiology (2005)
THU0551 Arthritis in sarcoidosis - a multi-centre study from india
Authors: A Jain, V Agarwal
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> 10–15% of sarcoid patients have associated arthropathy. Chronic arthritis is less common varying from 1–2% [1].Data on articular manifestations of the disease from India is sparse.[2] <h3>Objectives</h3> To study the clinical manifestations of sarcoid arthritis patients from India. <h3>Methods</h3> Case records of patients presenting to ten rheumatology centres from 2005 to 2016 with sarcoidosis were retrospectively reviewed. Joint involvement was assessed clinically, classified as acute or chronic depending on duration of symptoms lesser or greater than 6 months respectively. <h3>Results</h3> A total of 103 patients with sarcoid arthritis were reviewed. 58 patients were classified as Lofgren syndrome. Pattern of joint involvement revealed ankle as most commonly affected in both the groups (Table1). Wrist, MTP and PIP involvement was significantly more common in chronic sarcoid arthritis (table 1). Peripheral lymphadenopathy, plaques and uveitis were more frequent (p&lt;0.05) in chronic sarcoid arthritis (50%, 20.8%, 25% respectively) compared to those with acute sarcoid arthritis (16.5%,6.3%,6.4% respectively). 45 of 62 patients with acute arthritis with follow up details had achieved complete remission.15/24 patients with chronic sarcoid arthritis patients with a median follow up of 2 years had achieved complete remission with 14, 11 and 5 patients on steroids, methotrexate and hydroxychloroquine respectively. One patient with concomitant interstitial lung disease had died due to lung infection. <h3>Conclusions</h3> Acute oligoarthritis was the commonest presentation with ankle most commonly affected joint. Wrist, PIP, MTP involvement were more common in chronic sarcoidosis. One of the limitation was retrospective analysis. <h3>References</h3> Ungprasert P, Crowson CS, Matteson EL. Clinical Characteristics of Sarcoid. Arthropathy: A Population-Based Study. Arthritis Care &amp; Research. 2016;68(5):695–9. Govindarajan V, Agarwal V, Aggarwal A, Misra R. Arthritis in sarcoidosis. J. Assoc Physicians India. 2001;49:1145–7. <h3>Disclosure of Interest</h3> None declared
SAT0452 Influence of antirheumatic therapy administered in accordance with “treat to target” principles on heart rate variability and cardiovascular risk factors in patients with active early psoriatic arthritis
Authors: E Markelova, D Novikova, T Korotaeva, E Loginova, I Kirillova, L Denisov, D Karateev
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Psoriatic arthritis (PsA) is an inflammatory arthropathy, which is associated with range of co-morbid diseases and risk factors, such as dyslipidemia, obesity, metabolic syndrome, cardiovascular disease (CVD). Lower heart rate variability (HRV) is a well-established risk factor for CVD and all-cause mortality in the general population. <h3>Objectives</h3> to study dynamic of traditional risk factors (TRF) of CVD and parameters of HRV during antirheumatic therapy, administered inaccordance with "Treat to target" principles in PsA pts. <h3>Methods</h3> 44 (F.-21) DMARD-naive PsA pts, according to the CASPAR criteria, age 36 [27; 46] years (yrs.), PsA duration – 6 [4; 8] yrs, DAS 4.06 [3.51; 4.74]. TRFs of CVD were assessed according to ESC (2016): arterial hypertension (AH) – 11 (22.9%) pts, obesity (body mass index &gt;30kg/m<sup>2</sup>) – 11 (22.9%), abdominal obesity – 14 (29.2%), dyslipidemia – 31 (64.5%), family history of early CVD – 6 (12.5%), menopausal status – 5 (10.4%), smoking - 16 (33.3%). All pts were assessed for ECG, 24-h ECG monitoring, carotid ultrasound imaging. Antihypertensive therapy received all pts with AH. Methotrexate (MT) therapy was started in all pts with an escalation of the dose up to 25 mg/week subcutaneously. In case of no remission 3 months later, MT was added with biologic therapy: Adalimumab, Certolizumabpegol, Ustekinumab. 23 subjects were assessed after 18 months of therapy. <h3>Results</h3> After 18 months of therapy DAS and CRP level decreased significantly, p=0.001. DAS remission was achieved in 82.6% of pts. The incidence rate of AH (39% vs 39%), obesity (30% vs 21%), smokers (39% vs 39%), menopausal status (17% vs 17%), atherosclerotic plaques (39% vs 39%), did not change significantly. High-density lipoproteins increased significantly from 1.2 [1.1; 1.6] to 1.5 [1.2; 2.1]mmol/l, p=0.03. We didn9t find significant differences between baseline and after treatment levels of total cholesterol/low-density lipoproteins level: from 5.2 [4.6; 6.0] to 5.2 [4.5; 5.9] (p=0.47) mmol/l and from 3.4 [2.8; 3.8] to 3.3 [2.6; 3.6] (p=0.60) mmol/l. HRVs parameters didn9t change significant (table 1). <h3>Conclusions</h3> antirheumatic therapy of early PsA pts in accordance with "T2T" principles improves lipid profile but not HRVs parameters. Lower HRV is a risk factor for cardiovascular disease and mortality that demands the further studying its influence on the cardiovascular prognosis in PsA pts. <h3>Disclosure of Interest</h3> None declared
SP0024 Wearable technologies in research and clinical trials
Authors: M Mc Carthy
Journal: Annals of the Rheumatic Diseases (2017)

The use of wearable technology in clinical trials has the potential to be one of the most disruptive innovations in drug development. The cost and duration of the current clinical trial design has been under scrutiny for a number of years with the sustainability of the exiting model under question. A critical success factor is adequate patient recruitment and retention. Recent initiatives to redesign the clinical trial process have focused on the creation of trials that are more patient focused. A wealth of medical grade physiological data is now readily available from wearable technology, with the potential to create a new future where patients no longer have to visit research sites and where real-time data are available remotely. However, integrating wearables into a clinical trial is more complex than simply giving the patient a smartwatch and spontaneously generating clinically relevant data. Focusing on technology and sandwiching it into a trial is not a best practice. Wearables need to be viewed as a component of an overall patient-centric strategy rather than solutions in themselves. When creating a remote trial, simply shifting the burden from the sites to the patients, requiring them to carry out a number of tasks in an unsupported, uncontrolled environment is neither welcome nor sustainable. The process for successful selection and integration of wearables needs to take a number of criteria into consideration; clinical hypotheses, the value that is gained by the inclusion of wearables, the robustness of the data generated by the devices, and ensuring that the data adds clarity not additional complexity to the trial. The re-engineering of the clinical trial to create a patient focused trial goes beyond mere convenience. Wearables and sensor have the potential to generate digital maps of individual9s physical behaviours. Wearable technology is facilitating the remote capture of real life data but also has the potential to create new end points and outcome measures that are meaningful to the patient and could hold the key to a new clinical trials paradigm. <h3>Disclosure of Interest</h3> None declared